CD274 and cancer: Currently, clinical data on the combination of PD-1/PD-L1 inhibitors with VEGF inhibitors for the treatment of cancer are scarce, and future studies will focus mainly on determining the optimal combination and dose of VEGF inhibitors and PD-1/PD-L1 inhibitors for better anti-cancer efficacy.